Loading
VB
Ventyx Biosciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 26 Dec 2024.
Ventyx Biosciences, Inc.: what insiders have been doing
Ventyx Biosciences, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Between 18 October 2025 and 18 October 2026, 6 insiders published 11 filings.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
Compared with its exchange (5,808 companies, median 19 filings), a count of 11 filings is below the norm. Our records for Ventyx Biosciences, Inc. go back to 2021, with 2 purchases and 38 sales on the open market in total.
Over the last twelve months, not one insider purchase of Ventyx Biosciences, Inc. stock was filed. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
138
Thresholds
n/a
Buy Volume
€703,543
2 ops. · all time
Sell Volume
€39M
38 ops. · all time
Who traded when
BuySaleJohn Nuss2 sales
Raju Mohan1 buy
Sheila Gujrathi1 buy
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
Net income-US$116.3M
Last declaration on 4 March 2026
Declarations138 total
5,313 sharesCommon StockSEC:0002035970-26-000002:0
6,000 sharesCommon StockSEC:0001922353-26-000002:0
2,372,863 sharesCommon StockSEC:0001878125-26-000002:0
130,000 sharesCommon StockSEC:0001575202-26-000002:0
3,337,495 sharesCommon StockSEC:0001508910-26-000004:0
694,718 shares0Common StockSEC:0001508910-26-000002:0
116,668 shares0Common StockSEC:0001193125-25-326895:0
3,000 shares@ US$1.0349.1% of flowCommon StockSEC:0001193125-25-288157:0
1,767 shares@ US$1.0349.3% of flowCommon StockSEC:0001193125-25-288155:0
1,750 shares@ US$1.0350.7% of flowCommon StockSEC:0000950170-25-073813:0
3,000 shares@ US$1.0350.9% of flowCommon StockSEC:0000950170-25-073812:0
1,335,450 shares0Common StockSEC:0001415889-25-009374:0
11,844 shares0Common StockSEC:0001415889-25-009379:0
1,735,306 shares0Common StockSEC:0001415889-25-007849:0
130,000 shares@ US$2.312134.3% of flowCommon StockSEC:0001415889-24-030180:0
Canonical exit: 23 Mar 2025 (T+90)
116,668 shares0Common StockSEC:0001415889-24-029918:0
238,248 shares@ US$1.82563.1% of flowCommon StockSEC:0001415889-24-027673:0
Canonical exit: 20 Feb 2025 (T+90)
641,327 shares0Common StockSEC:0001415889-24-018253:0
25 of 138 declarations
About Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc. is a United States-based biopharmaceutical company listed on the Nasdaq under the ticker VTYX, with headquarters in San Diego, California, United States. Founded in 2018, Ventyx is a clinical-stage biotech focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company remains in the development phase and does not yet have an approved product on the market, so its equity story is still driven primarily by clinical execution, data readouts, and financing capacity. ([stockanalysis.com](https://stockanalysis.com/stocks/vtyx/company/?utm_source=openai))
Ventyx’s portfolio is centered on small-molecule programs that target inflammation-related biology. Its NLRP3 inhibitor franchise includes VTX2735, a peripherally restricted inhibitor, and VTX3232, a CNS-penetrant inhibitor designed to reach the central nervous system. The pipeline also includes assets for inflammatory bowel disease, notably tamuzimod, formerly VTX002, and VTX958, described as a selective allosteric TYK2 inhibitor. This mix of programs reflects a strategy of building differentiated oral medicines that could compete against biologics and other targeted therapies in large, chronic disease markets. ([ir.ventyxbio.com](https://ir.ventyxbio.com/news-releases/news-release-details/ventyx-biosciences-highlights-2025-pipeline-strategy-and?utm_source=openai))
Read moreShow less
From a competitive standpoint, Ventyx operates in a crowded and high-risk segment of biotech, where valuation depends on proof-of-concept data, safety, differentiation, and the ability to advance programs through later-stage development. Management has highlighted opportunities across autoimmune, inflammatory, neurodegenerative, cardiometabolic, and gastrointestinal indications, with particular emphasis on the potential of NLRP3 inhibition in systemic inflammation and neurological disease. In practical terms, the company’s market position is that of a platform-oriented clinical innovator rather than a commercial-stage pharmaceutical company. ([ir.ventyxbio.com](https://ir.ventyxbio.com/news-releases/news-release-details/ventyx-biosciences-highlights-2025-pipeline-strategy-and/?utm_source=openai))
Recent company updates have emphasized pipeline strategy and clinical milestones in 2025, including ongoing work around the NLRP3 portfolio and the broader inflammation pipeline. In 2026, Ventyx also appeared in market news tied to insider Form 4 activity and a reported strategic acquisition announcement from Eli Lilly, which reinforced external interest in its inflammation-focused platform. For investors in French-speaking markets, Ventyx should be viewed as a development-stage Nasdaq biotech in the United States with meaningful upside optionality, but also significant clinical, regulatory, and funding risk. ([ir.ventyxbio.com](https://ir.ventyxbio.com/news-releases/news-release-details/ventyx-biosciences-highlights-2025-pipeline-strategy-and/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
